Customize
Quick Links

Accreditation/
Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2019
Physicians’ Education Resource ®, LLC.
All rights reserved.

4th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application

4th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application


Saturday, December 14, 2019
InterContinental New York Times Square
300 West 44th Street
New York, NY 10036


Overview

The recent development of immunotherapies to treat cancer has transformed the way that clinicians think about managing their patients with many forms of malignancies. The speed at which basic science and clinical trial information continue to emerge in this area, however, creates practice and/or educational gaps for busy clinicians who strive to maintain state-of-the art care for their patients with cancer. This field is one of the most clinically relevant and exciting areas of novel drug development in oncology.

“But how do I use this information to manage my patients with cancer?”

This is the key question, and the one whose answer ultimately means the most for your patients. The 4th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application will answer that question. This exciting and fast-paced congress will provide a multi-module, curriculum-based program that focuses exclusively on immunotherapies and their application to the management of cancer. This intensive, 1-day interactive program will provide a comprehensive review of the key data sets that are most relevant to the application of these novel strategies for the clinician who manages some of the most difficult-to-treat forms of cancer. The program will focus on the practical application of recent clinical trial results that have shaped current and evolving clinical management, evolving biomarker information, the latest basic science findings, and the most highly anticipated clinical trials in the field.

Topics of particular interest will be optimal timing of checkpoint inhibitors, identification of patients with cell surface expression of a target antigen who would be good candidates for CAR T-cell treatment, using combination immunotherapies in patients with driver mutations (eg, EGFR/ALK), and the use of combination therapies targeting the IDO pathway in patients with advanced melanoma.

Target Audience

This educational program is directed toward oncologists, nurses, and pharmacists. Participants will be primarily those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving roles in the treatment of patients with cancer.


Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Explain current and evolving mechanistic approaches concerning how the immune system can be targeted in the treatment of cancer
  • Evaluate recent clinical trial findings on immuno-oncology strategies, and how they can be practically applied to the management of cancer in multiple lines of care
  • Discuss emerging methods to personalize care via the use of biomarkers and other methods to individualize the use of immuno-oncology strategies
  • Describe how common and uncommon adverse events, associated with the use of immuno-oncology strategies, can be proactively mitigated and managed
  • Detail important remaining clinical questions in the field, and highly anticipated ongoing clinical trials, that are evaluating emerging immuno-oncology strategies

Program Chairs

Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery
Professor of Molecular & Medical Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Chair, Melanoma Committee at SWOG
Los Angeles, California, USA

Naiyer A. Rizvi, MD
Professor of Medicine
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy Program
Price Chair, Clinical Translational Research
Columbia University Medical Center
New York, NY






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
2425262728
Filter By